Bharati, Joyita;
Jhaveri, Kenar D;
Salama, Alan D;
Oni, Louise;
(2024)
Anti–Glomerular Basement Membrane Disease: Recent Updates.
Advances in Kidney Disease and Health
, 31
(3)
pp. 206-215.
10.1053/j.akdh.2024.04.007.
Preview |
Text
Salama_Anti-glomerular basement membrane disease_ recent updates_VoR.pdf Download (1MB) | Preview |
Abstract
Anti–glomerular basement membrane disease is a small-vessel vasculitis involving the kidneys (∼90%) and the lungs (∼60%). Antibodies against the glomerular basement membrane are directly pathogenic in anti–glomerular basement membrane disease; however, recent research has highlighted the critical role of T cells. Novel autoantigens within the glomerular basement membrane are also now recognized. Atypical forms of the disease are reported along with preceding triggers, such as immune checkpoint inhibitors, immunomodulatory drugs, and vaccines. Kidney outcomes in anti–glomerular basement membrane disease remain poor despite significant improvement in patient survival in the last 2 to 3 decades. Treatment typically relies on combined plasmapheresis with intensive immunosuppression. Dialysis dependency at presentation is a dominant predictor of kidney outcome. Histologically, a low (<10%) percentage of normal glomeruli, 100% crescents, together with dialysis dependency at presentation, is associated with poor kidney outcomes. In such cases, an individualized approach weighing the risks and benefits of treatment is recommended. There is a need for better ways to stop the toxic inflammatory activity associated with this disease. In this narrative review, we discuss recent updates on the pathogenesis and management of anti–glomerular basement membrane disease relevant to patients of all ages.
Archive Staff Only
 |
View Item |
